On Nov. 2, the Jerusalem Quartet flooded the Mahaney Arts Center with passionate string music ranging from classical to modern. Celebrating their 30th season, Jerusalem Quartet returned to Middlebury ...

Yuhan-Kimberly, a joint venture between Korea’s Yuhan Corp. and America’s Kimberly Clark, has been chosen as one of the ...

Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a ...

In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...

In Pictures The denim fair Kingpins celebrated its tenth anniversary edition in Amsterdam last week. A highlight of the fair ...

In terms of improving the wellbeing of all mankind, China and the US should give full play to their respective advantages and ...

SEOUL, Oct. 28 (Yonhap) -- Yuhan Corp., a South Korean biopharmaceutical company, said Monday its third-quarter net profit ...

Shim Jae-jeong, a professor of respiratory and allergy at Korea University Guro Hospital, won the 'limited tuberculosis and ...

Hope Medicine Inc. reported positive interim results for monoclonal antibody HMI-115 in a phase II endometriosis trial that ...

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies. BioWorld Asia Deals ...